1.50
+15.38%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cabaletta Bio
From its filings with the US Securities and Exchange Commission
Cabaletta Bio is based in Philadelphia, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CABA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $167.9m. At that date it held total assets of $165.1m and shareholders' equity of $112.1m.
Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells that are engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy transitional, naïve B cells. This approach has demonstrated the potential to reset the immune system and result in meaningful clinical responses without chronic therapy requirements in patients. The efficacy and safety of rese-cel was recently reviewed along with all other commercial and academic constructs in development in a February 2026 Nature Biotechnology publication.
In December 2025, we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome. In addition, we have ongoing Phase 1/2 trials evaluating rese-cel with a standard preconditioning regimen, fludarabine and cyclophosphamide, in systemic lupus erythematosus, or SLE, in patients with active lupus nephritis, or LN, or active SLE without renal involvement, systemic sclerosis, or SSc, and generalized myasthenia gravis, or gMG.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Oct 2019
- Employees
- 154
- Website
- cabalettabio.com ↗
- Head office
- 2929 ARCH STREET, PHILADELPHIA, PA, 19104
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Steven NichtbergerChief Executive Officer, President, Chairman of the Board, Co-Founder, since 2017$8.1m
- Mr. Anup MardaChief Financial Officer$1.5m
- Dr. Gwendolyn Binder-SchollPresident - Science and Technology$3.3m
- Mr. Michael GerardGeneral Counsel, Secretary
- Dr. David ChangChief Medical Officer$3.3m
- Dr. Arun DasChief Business Officer
- Dr. Catherine BollardIndependent Director$241,810
- Dr. Scott BrunIndependent Director$246,810
- Mr. Richard HenriquesIndependent Director$242,310
- Mr. Mark SimonIndependent Director, since 2018$245,310
- Ms. Shawn TomaselloIndependent Director$234,810
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 35
- Social
- 43
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Technology: Cabaletta Bio Inc is equipped with advanced technology that positions them at the forefront of the industry.
- Strong Intellectual Property: The company holds a robust portfolio of patents and trademarks, providing a solid foundation for their products and services.
- Expert Team: Cabaletta Bio Inc boasts a highly skilled and experienced workforce, comprising experts in various relevant fields.
Weaknesses
- Limited Market Presence: The company currently has a relatively small market share, hindering their ability to compete with larger competitors.
- Dependency on Funding: Cabaletta Bio Inc heavily relies on external funding sources, which may pose challenges in terms of sustainability and financial stability.
- Lack of Product Diversification: The company's product lineup is currently focused on a specific niche, potentially exposing them to market volatility.
Opportunities
- Growing Market Demand: The increasing demand for innovative medical solutions presents an opportunity for Cabaletta Bio Inc to expand their customer base.
- Collaborative Partnerships: Forming strategic alliances with other industry players can enable the company to access new markets and resources.
- Global Expansion: Cabaletta Bio Inc can explore international markets to capitalize on emerging opportunities and diversify their revenue streams.
Threats
- Regulatory Challenges: Stringent regulations imposed on the healthcare industry can create hurdles for the company's product development and commercialization.
- Intense Competition: Cabaletta Bio Inc faces competition from both established companies and emerging startups, putting pressure on their market position.
- Technological Advancements: Rapid advancements in technology may render the company's existing solutions obsolete if they fail to keep pace with industry trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.